



4th May 2004

ASX Companies Announcements Office, Sydney

Via:- asx.online.com

VRI APPOINTS SCIENTIFIC AND MEDICAL ADVISORY BOARD.

VRI BioMedical Ltd is pleased to announce that Prof Ron Penny, AO, and Professor Terry Bolin have accepted the invitation to join the inaugural VRI Scientific and Medical Advisory Board. This provides VRI with independent input and critical guidance into the scientific and clinical trials being conducted by VRI, which will further assist VRI to produce and market products which satisfy the demand for effective immunological and intestinal health products. Both Professor Bolin and Professor Penny are internationally renowned clinicians and researchers in their respective areas of gastroenterology and clinical immunology, the two areas in which VRI is developing and commercialising health products.

Professor Ron Penny AO, DSc, MD, BS, FRACP, FRCPA is one of Australia's leading immunologists, and is currently Emeritus Professor of Medicine – UNSW, Senior Clinical Advisor - NSW Health, Chairman of the NSW Blood Products Advisory Committee and Chairman of the NSW SARS Task Force. He is a Member of the NSW Expert Advisory Group on Drugs, the Ministerial Advisory Council on Medical and Health Research and NSW General Practice Council. He has published over 350 medical and scientific papers in national and international journals.

Professor Terry Bolin MD(NSW) BS(Syd) FRACP FRCP(Lond) FRCP(Edin) DCH(Lond), is a gastroenterologist, Associate Professor of Medicine at the University of New South Wales, Visiting Physician to the Gastrointestinal Unit at The Prince of Wales Hospital, Sydney, and President of the Gut Foundation. He has published over 100 medical and scientific papers in national and international journals, particularly in the areas of infection and nutrition in developing countries. His other major interests relate to bowel disorders irritable bowel, Colitis and Crohn's disease and prevention of bowel cancer.

The Managing Director of VRI, Dr Peter French, stated that the ability of VRI to attract people of such calibre and reputation in their medical fields to join the advisory board indicated that VRI had reached a state of maturity as a biotechnology company. "A key success factor and differentiator for VRI's commercialisation is the robust scientific and clinical data supporting our products," Dr French said. "These appointments will further enhance the confidence that healthcare professionals, shareholders and the public have in VRI's science, and therefore the efficacy of our products."

VRI BioMedical is a probiotics company "bringing science to wellness™" through its focus on commercialisation of products for health maintenance and disease prevention based on the intellectual property arising from its extensive scientific and clinical R&D program.

FOR FURTHER INFORMATION: Dr Peter French, Managing Director, VRI BioMedical Ltd, Tel (02) 9209 4268